肥胖
药物发现
医学
重症监护医学
减肥
药品
肥胖管理
糖尿病
生物信息学
药理学
生物
内分泌学
作者
Timo D. Müller,Matthias Blüher,Matthias H. Tschöp,Richard D. DiMarchi
标识
DOI:10.1038/s41573-021-00337-8
摘要
Enormous progress has been made in the last half-century in the management of diseases closely integrated with excess body weight, such as hypertension, adult-onset diabetes and elevated cholesterol. However, the treatment of obesity itself has proven largely resistant to therapy, with anti-obesity medications (AOMs) often delivering insufficient efficacy and dubious safety. Here, we provide an overview of the history of AOM development, focusing on lessons learned and ongoing obstacles. Recent advances, including increased understanding of the molecular gut–brain communication, are inspiring the pursuit of next-generation AOMs that appear capable of safely achieving sizeable and sustained body weight loss. The development of therapies that are capable of safely achieving sizeable and sustained body weight loss has proved tremendously challenging. Here, Müller et al. provide an overview of the history of anti-obesity drug development, focusing on lessons learned, ongoing challenges and recent advances in the field.
科研通智能强力驱动
Strongly Powered by AbleSci AI